

Study of Risk Factors for Vascular Events in Sick Cell Disease Traced By Neuroimaging and Trans Cranial Doppler Changes

دراسة الأحداث الوعائية لمرض فقر الدم المنجلي المتتبعه بمتغيرات الرنين المغناطيسي والذبذبة الدماغية

Dr. Talib Abduljaleel Jasim ; Pediatric consultant; M,B,Ch,B,/ C,A,B,P,
Prof Associate; kufa university, Alzahraa Hospital ,Najaf
E-Mail : drtalibmadany@yahoo.com

الخلاصة :

خلفية البحث : الضربة الصامتة والعلنية تشمل 10-20 % من تعقيد مرض خلية المنجل. هناك زيادة خطر من المراضة و أحيانا يعطل الإدراك العصبي.

الهدف : لتمييز عامل الخطر الأكثر أهمية للأحداث العصبية باستعمال الرنين المغناطيسي و الذبذبة الدماغية .

المنهجية : الدراسة التحليلية الوصفية نفذت خلال فترة سنة واحدة في مستشفى الزهراء على ثلاثون مريض بمرض خلية المنجل. الفحوصات المخبرية عملت كجزء من المتابعة المتضمن، مصل الفريتين ،والرنين المغناطيسي، وفحص الذبذبات الدماغية.

النتائج : من مجموع 30 مريض، وجد فقط مريض واحد مصاب بضربة واضحة، اثنان بالضربة الصامتة و 14 مريض وجد شذوذ في نتائج الذبذبات الدماغية. أغلب هذه الأحداث وجدت في المرضى ذوي خضاب الدم المتدني (p قيمة 0.015)، حساب كريات الدم الحمراء منخفض (p قيمة 0.001)، وكذلك في زيادة تركيز خضاب الدم نوع (المنجلي). إن زيادة عمليات نقل الدم له مردود ايجابي ضد الضربة

الاستنتاج : خطر الضربة المخية يتعلّق مباشرة، بشدة فقر الدم ، تركيز عالي من خضاب الدم المنجلي.
التوصيات : المراقبة المبكرة والمنظمة لمجري الدم المخي بالذبذبات الدماغية وبالرنين المغناطيسي وتحسين ظروفه العامة قد يساعد في دفع الخطورة عنه.

ABSTRACT;

[Background : silent and overt stroke comprise 10-20% of complication of sickle cell disease. There was great risk of morbidity and mortality, some time with neurocognitive dysfunctions

Objective: to identify the most important risk factor for neurologic events using MRI and TCD as aid for diagnosis.,

Method: descriptive study carried out over one year period in alzahraa hospital .thirty patients with sickle cell disease enrolled. All test done as part of follow up, which include ,serum ferritin, blood count, MRI, and TCD. Data was analyzed by using SSPS version 18.

Results: from total 30 patients enrolled, only one patient found to have overt stroke, two other with silent stroke and 14 patient got abnormal TCD study. Most of CNS events found in patients with low hemoglobin(p value 0.015),low red blood counts(p value 0.001),and those with high hemoglobin S concentration. Blood transfusion noticed to be protective against stroke.

Conclusion: risk of cerebral stroke was related to, severity of anemia ,high concentration of hemoglobin S

Recommendations: regular monitoring of cerebral blood flow by TCD and MRI decreased morbidity and mortality, together with improvement in social, and conditional affairs of patients.

Key words ; sickle cell ;stroke; transcranial Doppler

INTRODUCTION

Sickle cell disease (SCD) refers to a group of disorders in which the red blood cell undergoes sickling when deoxygenated. Sick red cell adhesion to vascular endothelium appears to be the nidus for vaso-occlusion, rather than simply stiff sickled cells blocking the microvasculature. If a starting point can be identified, it might be the large numbers of stress reticulocytes which have adhesion molecules expressed on their surfaces that are not present on more mature red cells ^(1,2). Typical manifestations include recurrent pain and progressive incremental infarction. Children with sickle cell disease, a chronic hemolytic anemia, present with a wide variety of neurological syndromes, including ischemic and hemorrhagic stroke ^(3,4).

Concentration of Sick hemoglobin(Hb S) is a factor in that gelation of HbS occurs at concentrations greater than 20.8 g/dL (the normal cellular Hb concentration is 30 g/dL). Fetal hemoglobin (HbF) have an inhibitory effect on gelation ⁽⁵⁾.

Sickle RBC adhesion in post capillary venules can cause increased micro vascular transit times and initiate vaso-occlusion ⁽⁶⁾.

Stroke may be defined as an acute syndrome caused by restriction of cerebral blood flow with resultant ischemia and neurologic symptoms. Transient ischemic attack may be considered as a brief episode of neurologic dysfunction caused by focal brain ischemia, with clinical symptoms typically lasting less than one hour, and without subsequent neurologic or neuroradiographic evidence of cerebral infarction ⁽⁷⁾. A “silent” cerebral infarct has been defined as an area of abnormally increased signal on intermediate and/or T2 weighted pulse MRI (magnetic resonance imaging) sequences compatible with brain infarction, without associated neurologic symptoms with a normal neurologic examination ^(8,9,10)

overt stroke and silent stroke occurs in SCD as 10% and 20% respectively ⁽⁸⁾. computed tomography (CT) scan and MRI imaging remains the initial test of choice for assessment and trans cranial Doppler (TCD) is the imaging of choice for stroke prevention. ⁽⁹⁾. In patients who have presented with acute stroke, large infarcts in an arterial territory or in the border zones between anterior and middle cerebral arteries have been described ⁽¹⁰⁾. in association with endothelial hyperplasia, fibroblastic reaction, hyalinization and fragmentation of the internal elastic lamina, and thrombi in large and small vessels. In addition to the typical small necrotic lesions in the border between the cortex and the subcortical white matter, acute demyelination ⁽¹¹⁾.

The widespread use of MRI and MR angiography (MRA) in the 1990s resulted in an appreciation of the extent and location of lesions not only associated with overt stroke but also those related to silent cerebral infarcts. Effective stroke prevention has become possible through the utilization of trans cranial Doppler ultrasonography (TCD). ⁽¹²⁾ TCD is a safe, noninvasive, well tolerated, relatively low-cost procedure in which the velocity of blood flow can be measured in intracranial vessels using an ultrasound probe placed over the temporal bone to screen for cerebrovascular disease ⁽¹³⁾. In a comparison with conventional angiography, TCD showed a sensitivity of 90% and specificity of 100% for the diagnosis of abnormality.

Use of Doppler ultrasonography had become an important way to identify extra cranial carotid stenosis based on a derivation of the Bernoulli principle, which is that in the area where the vessel is narrowed, the velocity of blood flowing in that vessel is increased. TCD seemed a more direct diagnostic approach. The TCD was also attractive because it was harmless, painless, and generally well tolerated, even by children, and did not require sedation. It was also portable and low cost compared with other methods. It was known that cerebral blood flow and flow velocity as estimated by TCD are increased in the anemic condition owing to the lowered oxygen-carrying capacity of the blood. It was evident from work by Adams et al ⁽¹⁴⁾. that the evolving velocity standards of TCD for stenosis in adults would not apply in SCD owing to the impact of young age and anemia.

The early use of TCD in adults had shown that the normal velocity (time-averaged mean of maximum blood flow as opposed to systolic or diastolic) was approximately 60 cm/s. It was determined that the expected middle cerebral artery velocity in healthy children was approximately 90 cm/s, and in children with SCD without overt stroke it was approximately 130 cm/s, elevated on the basis of young age and severe anemia. When the angiogram showed severe stenosis, the velocity was always greater than 190 cm/s and often much higher except in cases of severe stenosis, in which very low velocities were recorded (less than 70 cm/s). ⁽¹⁵⁾ Arbitrary velocity cutoff points less than 170 cm/s represented “normal” or average risk, 170 to 199 cm/s was called “conditional” and was associated with moderate risk, and 200 cm/s or greater was called “abnormal” or high risk. A risk of stroke during the next 36 months of 13% per year was observed. The use of chronic transfusion to prevent secondary stroke, which can occur in 60%-90% after the primary stroke, has been widespread since the

1970s and has reduced the risk of this occurrence to approximately 15%. And the discontinuation of chronic transfusion after 1–2 years, or even 5–12 years⁽¹⁶⁾, is associated with a high risk of stroke recurrence.

AIM; To identify the common risk factor for cerebrovascular events in sickle cell disease using neuroimaging and trans cranial Doppler aids.

PATIENT AND METHODS

Prospective analytic study carried out on 30 patients with SCD who has been diagnosed previously on the bases of history, examination and Hb. Electrophoresis(Variant 1 , Biorad 1999.) registered in the hereditary blood diseases center in Al- Zahraa Teaching hospital in AL-Najaf , from the first of February to the end of November 2013, inclusion criteria includes patients have SCD with sickle hemoglobin more than 50% of total ,both sex ,age range 2 to 16 years. Exclusion criteria includes sickle cell trait, patient more than 16 years and patients who have other diseases like congenital heart diseases. Full history include, age of diagnosis the disease, family history of SCD, transfusions, chelating agent, Hydroxyurea,(dose and compliance).physical examination include any abnormal neurological finding included one sided weaknesses and / or sensory changes (numbness, tingling sensation), balance, vision loss, slurring of speech, facial asymmetry, headache, seizures, and behavior disturbance.

Blood samples(as part of usual patients follow-up) with EDTA tube and sent for CBC. (hematology analyzer ,Ruby 2010), and serum tube sent for serum ferritin by Mini Vidas, Biomeurx 2009).Brain MRI done in the in Al Zahraa hospital,(Open Magnet field 0.2 tesla, Siemens 2004), reports revised by radiologist. TCD done in Al Forat Al Aosat center for the neurological diseases at Al Sadir hospital in Najaf, (Ez-Dop 1071/ DWL company) and the report revised by the unit specialist

Statistical analysis was done using SPSS program V.20, data were expressed and comparisons of proportions was performed using independent T- test, P-value of < 0.05 was considered as statistically significant. Logistic regression analysis was also done for the analysis of different variables, and for each variable the mean, standard deviation and 95% confidence interval (CI) were assessed.

RESULTS :

Total number of patients included are thirty, 16 males and 14 females, age range 2-16 years (mean 11.06 ± 4.16)

Only one patient have overt stroke, occurred 3 years ago as sudden onset of loss of consciousness followed by gradual improvement, other patients have normal history and examination. Most of them have good school performance but some of them stop their education due to low socioeconomic state..




figure -1- MRI finding for studied patients

figure 1 demonstrate, that, one (3.33%) patient show feature of old insult by MRI (large encephalomalacia area seen at left temporo-parietooccipital region with flecks of calcification), 2 (6.66%) patient have features of silent stroke (2 lacunar infarctions in the left periventricular area and the other show 1 small lacunar infarction in the right periventricular area), 27 (90%) patients have normal MRI.

figure 2 shows that, 16 patients (53.33%) have cerebral artery blood velocity of MCA less than 170 cm/sec., while 8 (26.66%) have velocity of MCA 170-199 sc/sec., 4 (13.33%) have velocity of MCA 200-230 cm/sec., one (3.33%) have velocity of MCA more than 230 cm/sec., and one (3.33%) have velocity of MCA less than 50




figure -2- speed of blood velocity at MCA using TCD.

Patients categorized in to two groups; First group with CNS events include 14 patients (46.66%) , this group includes those with overt and silent stroke and patients who are at risk for stroke that appear as abnormal blood velocity at middle cerebral artery(MCA) by TCD. Second group were sixteen patients(53.33%),without any neurological finding. For age deference there was no statistical difference between both groups since 10 patients (62.50%) out of 16 without CNS events are above 10 years and 10 patients (71.42%) out of 14 who got CNS events are above 10 years.

Table(1): CNS complications in relation to hematological variability

Variables		No CNS Events N=16	CNS Events N=14	P value	Mean (\pm SD)	95% confidence Interval Lower Upper	
Hb. Level	<8mg/dl	1 (6.25%)	11(78.57%)	0.015 (<0.05)	8.63 (1.51)	8.06	9.19
	\geq 8mg/dl	15(93.75%)	3(21.42%)				
W.B.C Count	<11*10 ³	12(75.00%)	8(57.14%)	0.253	11.13 (7.00)	11.13	13.75
	\geq 11*10 ³	4(25.00%)	6(42.85%)				
Platelet Count	150-400	12(75.00%)	9(64.28%)	0.259	357.70 (110.78)	316.33	399.06
	\geq 400	4(25.00%)	5(35.71%)				
R.B.C Count	<4*10 ⁶	9(56.25%)	12(85.71%)	0.001 (<0.05)	3.42 (1.10)	3.01	3.83
	\geq 4*10 ⁶	7(43.75%)	2(14.28%)				
	>180 cc/kg	8(50%)	3(21.42%)	0,012			
RBC \year	<140 kg	8(50%)	11(78.5%)				

Table 1 demonstrate that from 16 patients without CNS events only one patient (6.25%) have low hemoglobin level, while 11(78.57%) out of 14 patients with abnormal neurologic events demonstrate low hemoglobin level , p value is significant (P=0.015).This finding strengthened

by finding that , patients who received more than 180 milliliter of packed red cell per year had less CNS complications than those who were on episodic transfusions, the p-value was less than 0.05. Regarding R.B.C count 9 patients (56.25%) have low R.B.C count out of 16 patients with no CNS events while low count seen in 12 patients (85.71%) out 14 with CNS events , p value was 0.001.regarding white cell count and plate late there was no statistical difference between both groups .

Table (2): Relation between serum ferritin and hemoglobin type on CNS events

Variables		No CNS Events N=16	CNS Events N=14	P value	Mean (±SD)	95% confidence Interval	
						Lower	Upper
Hb S %	50-70	11(68.75%)	2(14.28%)	0.03 (<0.05)	71.65 (12.93)	66.82	76.48
	>70	5(31.25%)	12(85.71%)				
Hb. F%	<20	14(87.50%)	13(92.85%)	0.343	8.08 (5.06)	6.19	9.97
	≥20	2(12.50%)	1(7.14%)				
Hb. A %	<10	7(43.75%)	10(71.42%)	0.124	12.23 (11.98)	7.75	16.7
	≥10	9(56.25%)	4(28.57%)				
S. ferritin mg/dl	<1000	7(43.75%)	6(42.85%)	0.925	2663.06 (2898.2)	1580.85	3745.2
	≥1000	9(56.25%)	8(57.14%)				

Table 2 clarified that 12 patients with CNS events out of 17 patients having Hb.S>70% while only two patients with CNS events out of 13 having Hb.S 50-70% of total hemoglobin. The p value is (P=0.030).The confidence interval lies between level of hemoglobin S (66.8% and 76.4%) .

For adult and fetal hemoglobin level and Ferritin it was shown to have no statistical differences in relation to cerebral events

Table (3) : Relationship between patient therapy and neurological outcome.

Variables		No CNS Events N=16	CNS Events N=14	P value
Chelating Agents	Effective use	8 (50.00%)	9 (64.28%)	0.323
	Not	8 (50.00%)	5 (35.71%)	
Hydroxyurea	Use	7 (43.75%)	7 (50.00%)	0.652
	Not	9 (56.25%)	7 (50.00%)	

There is no statistically significant difference in use of chelating agents and Hydroxyurea for both groups

DISCUSSION :

As a complication, overt stroke and silent stroke occur in 10% and, 20% respectively in CSD⁽¹⁷⁾. The silent stroke associated with neurocognitive dysfunction and diminished educational performance and is a risk factor for additional silent strokes or overt stroke but the best management of silent cerebral infarcts is unknown at this time⁽¹⁸⁾ so it is much better to focus on the prevention of these complications rather than treating it.

For the effect of hemoglobin level this study found that 11 (78.57%) out of 14 patient with neurological events show low level of Hb. In comparison with only 1 (6.66%) out of 16 patient with out, neurological events, p value(P=0.015) this mean that neurological events associated with lower Hb. level. the same result done in a large prospective multicenter study in France⁽¹⁹⁾.

Eight patients (50%) out of 16 patients without neurological events group received more than 180 milliliter of packed red cell, for each kilogram body weight per year trying to elevate hemoglobin level more than 8 g/dl, while only 3 (21.42%) out of 14 patient with neurological events, received blood in the same way in the last 2 years, p-value(P=0.012). Under transfusion found in patients who live far away from hospital, and some have poor economic state to comply well with the their visit.

Low hemoglobin, high white blood cell, seem to be risk factors for overt ischemia in SCD. For hemorrhagic stroke, only low hemoglobin and high white blood cell count were found to be predictors in sickle CNS disease. Real data indicate that nocturnal hypoxia, related to anemia, might increase the risk of CNS events⁽²⁰⁾.

American study have shown that children with initially abnormal TCD velocities (>200cm/s) treated with regular transfusion for 30 months or more, resulted in reduction of flow to less than 170cm/s. Discontinuation of transfusion program led to an unacceptably high rate of TCD reversion back to high risk (>200cm/s) velocity⁽²¹⁾. The long term effect of transfusion, including iron over load has recently become easier to manage with introduction of an oral iron chelator. Transfusion also has significant effect in reduction of inflammatory response and prevent reduction of nitrous oxide level through cessation of hemolysis in SCD⁽²²⁾.

It was found that blood transfusion associated with lower ischemic and lower cerebral blood velocities. The use of chronic transfusion for the prevention of primary stroke is recommended in the late 1990s^(21,22).

Regarding the platelet count, unlike foreign studies, there was no statistical difference between the two groups, in general platelet count show mild increment in SCD⁽²³⁾, but there is an evidence that the high platelet count involved in the mechanism of stroke and lead to neurological events⁽²⁴⁾, This may be due to small number of the studied patients comparing with these studies.

White blood cell count variability show no difference between the two groups however leukocytosis occur in SCD but leukocyte increases to higher levels in hemorrhagic stroke rather than ischemic stroke⁽²³⁾.

platelets and leucocyte activation, which might affect endothelial function, are inversely related to the mean overnight oxygen saturation in child with SCD, and there is evidence for increased level of markers of cellular and endothelial adhesions⁽²⁵⁾. Regarding R.B.C count, 12 (85.71%) out of 14 patients of neurological events show decrease RBC count compare with 9 (56.25%) out of 16 patients without neurological events this make a significant difference between the two groups (P=0.001). Reduction of red blood cell count reflects the degree of anemia due to chronic hemolysis, with its pathological and noxious effect on microcirculation of the brain⁽²⁶⁾. Hemoglobin-S- level measurement by Hb. electrophoresis reflect the severity of the disease and then presence of complications⁽²⁴⁾, 12 (85%) out of 14 patients of neurological events group show Hb.S level more than 70% of total Hb. while 5 (31.25%) out of 16 patients who have no neurological events got this level (P=0.030) this mean that the neurological complications is more with the increasing Hb.S level.

Trying to decreased the level of hemoglobin S level to below 30% ,using either Hydroxyurea or blood transfusions .will help to decreased the risk of stroke recurrence to between 10% and 20%⁽²⁷⁾.

Fetal hemoglobin has a role of a protective agent against Hb.S by the prevention of polymerization of Hb.S under deoxygenating state thus decrease complications. Many factors lead to increase its level, the genetic presentation of the disease itself (sickle-thalassemia or Hb.S-b thalassemia) or by using drugs that lead to increase its level like Hydroxyurea⁽²⁷⁾. The level of Hb.F should be more than 20% in order to predict its effect on the disease. Since all

studied patients got fetal hemoglobin below 20% there was no statistical difference this may be due to most of them have Hb.S level more than 70% ,and all patients were not on Hydroxyurea therapy..

Serum ferritin level increases in SCD as results of chronic hemolysis or due to frequent blood transfusion ⁽²⁴⁾ there is no statistical significant difference between the two groups , this may be due to its direct effects on the CNS is doubtful since it cannot cross blood brain barrier .There are some evidence that support worsening clinical outcome in the presence of severe iron overload. Serum ferritin may be unreliable for estimating body iron because vaso-occlusive crises are associated with elevated serum ferritin. However monitoring of serum ferritin may be useful while the patients in the steady state⁽²⁸⁾.

It has been found that young children with SCD were at high risk of stroke⁽¹⁵⁾The highest occurs at ages below 10 years and above 50 year, patients age also affects the presence of the CNS complications as the highest mortality occurs in ages below 10 years and above 50 years⁽²⁴⁾.

For age as risk factor this study denote no significant difference between those with neurological abnormalities and those without changes, this due in part to that most of our patient were below ten years of age and they were on regular transfusion program rather than episodic transfusion, trying to keep their hemoglobin at reasonable level. The use of Hydroxyurea decrease CNS events by increasing Hb.F level⁽²⁹⁾ but in our study there was no statistical difference between the two groups, which may be explained by the fact, that most of our patients were not on effective dose, due to unavailability of the drug and its expensive price in the market. Its use was reduced in sickle cell patients as a result of presence of free hemoglobin in the circulation. This positive effect might improve the circulation due to modifying the vasodilation of circulation⁽³⁰⁾.

There are emerging data that Hydroxyurea may have beneficial effect in primary or secondary prevention of stroke in children , its role relative to that of blood transfusion has been defined by prospective trials. Until more data available blood transfusion is the modality of choice in treatment and prevention of stroke in SCD⁽³⁰⁾.

CONCLUSIONS:

- 1- Risk of CNS events (overt or silent stroke) is directly related to low hemoglobin level, high percentage of sickled hemoglobin and low or irregular blood transfusion.
- 2- Chelating agents and Hydroxyurea, although improving the general condition of patient with SCD, they were not able to prevent or decrease the consequences of CNS complications.

RECOMMENDATIONS :

- 1- Early detection of factors that increased risk of stroke is important to raise our awareness about the CNS complications using frequent TCD and MRI specially for patients less than 10 years .
- 2-Maintenance of hemoglobin level by frequent blood transfusion with iron chelating agent to the level that improve brain perfusion and prevents cerebral arteries stenosis.

REFERENCES:

1. Parise LV, Telen MJ. Erythrocyte adhesion in sickle cell disease .*CurrHematol* 2003;(2);102-8.

2. Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. *Curr Opin Hematol* 2006;**13(1):40-4**.
3. Johnson L, Carmona-Bayonas A, Tick L. management of pain due to sickle cell disease. *J pain palliat care pharmacother*. 2008;**22(1):51-4**.
4. Chaing EY, Frenette PS. Sickle cell vaso-occlusion. *Hematol Oncol Clin North Am*. Oct. 2005;**19(5):771-84**.
5. Zen Q, Batchvarova M, Twyman CA, Eyler CE, Qiu H, De Castro LM, et al. B-CAM/LU expression and the role of B-CAM/LU activation in binding of low and high density red cell to laminin in sickle cell disease. *Am J Hematol*, Feb 2004;**75(2):63-72**.
6. Albers, G. W., Caplan, L. R., Easton, J. D., Fayad, P. B., Mohr, J. P., Saver, J. L., et al. (2002). Transient ischemic attack—proposal for a new definition. *New England Journal of Medicine*, **347**, 1713–1716. *iat* 2011 .sep **159(3) ;472-8**. J. J. Pea
7. Hines PC, McKnight TP, Scto W. *Journal of Medicine* .CNS event in SC, 321. 1525, 2008. Gan **113**.
8. Winnow N, Meiham ER. SCD and Stroke in pediatric population. *Neuroimaging Clin. N. AM. journal*; 2003 may, **13(2):185-96**.
9. Ganesan V. (2006) Recurrence after childhood ischemic stroke. *Circulation stroke. circulation. am Jou Hematol*. **114;2170-2177**
10. Makani J (2004) Stroke in sickle cell disease in Africa: case report. *East Afr Med J* **81: 657-659**
11. Adams, R, McKie, V., Nichols, F., Carl, E., Zhang, D. L., McKie, K., et al. (1992). The use of transcranial ultrasonography to predict stroke in sickle cell disease. *New England Journal of Medicine*, **326**, 605–610.
12. Hsu LL. (2003) Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. *J Pediatr Hematol Oncol* **25: 622-628**.
13. Adams RJ, Nichols FT, Stephens S, Transcranial Doppler: the influence of age and hematocrit in normal children. *J Cardiovasc Ultrasonogr*. 1988;**7(3): 201-205**.
14. Robert J. Adams, MS, MD Big Strokes in Small Persons *Arch Neurol*. 2007;**64(11):1567-1574**
15. Scothorn, D. J., Price, C., Schwartz, D., Terrill, C., Buchanan, G. R., Shurney, W., (2008). Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. *Journal of Pediatrics*, **140**, 348–354.
16. **Nelson textbook of pediatrics**, 19 ed. chapter 456.1 Sickle Cell Disease Michael R. DeBaun, Melissa Frei-Jones,
17. Buchanan, G. R., DeBaun, M. R., Quinn, C. T., & Steinberg, M. H. (2004). Sickle cell disease. **Hematology (American Society of Hematology Educ Program)**, 35–47.
18. Bernaudin, F., Verlhac, S., Freard, F., Roudot-Thoraval, F., Benkerrou, M., Thuret, I., et al. (2000). Multicenter prospective study of children with sickle cell disease: Radiographic and psychometric correlation. *Journal of Child Neurology*, **15**, 333–343.
19. Bakhshi S et al .Acute encephalopathy in sickle cell disease. *Arch Dis Child* (2003) **87;541-542**.
20. Robert J. Adams. Big Stroke in Small Persons. *Arch Neurol*, 2007; **64(11);1567-1574**.
21. Steinberg MH, Brugnara C. Pathophysiological-based approaches to treatment of sickle cell disease. *Annu Rev Med*. 2003; **54**;99-112
22. Editors: Rudolph, Colin D.; Rudolph, Abraham M.; Hostetter, Margaret K.; Lister, George; Siegel, Norman J. Title: *Rudolph's Pediatrics, 21st Edition*, Chapter 19 - Blood and Blood-forming Tissues, **1532-39**. 2003.
23. Platt OS. Preventing stroke in sickle cell anemia. *Engl J Med*. 2005; **353(26):2743- 2745**

24. Setty BY et al .Hypoxemia in sickle cell disease;biomarkermodulationand relevance to disease pathphysiology(2003).*Lancet* 362;1450-1455
25. Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions to prevent stroke in sickle cell disease. *N Engl J Med.* 2005;**353(26):2769-2778**.
26. Ware RE et al.Prevention of secondary stroke and resolution of transfusion iron overload in children with SCD using Hydroxyurea and phlebotomy.(2004).*J Peadiatr* 145;346-352.
27. Scothorn, D. J., Price, C., Schwartz, D., Terrill, C., Buchanan, G. R., Shurney, W., et al. (2002). Risk of recurrent stroke in children with sickle cell receiving blood transfusion therapy for at least five years after initial stroke. *Journal of Pediatrics*, **140**, 348–354
28. Adette INATI.managment of iron toxicity in sickle cell disease;issue,options,andguidance. *Iron Journal Club*.vol 3;NO2;2009;**75-79**.
29. Rother RP,Bell L, HillmenP,GladwinMT.The clinical sequalae of intravascular hemolysis ;anovelmechanisim of human disease.*JAMA*,2005;**293(13);1653-1662**.
30. Gulbis B,HabermanD,Dufour D, use of Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events;*Blood* .2005;**105;2685-2690**.